<DOC>
	<DOCNO>NCT00600626</DOCNO>
	<brief_summary>This trial conduct Europe Asia . The aim trial compare basal bolus treatment insulin aspart insulin NPH biphasic insulin aspart treatment blood glucose control type 2 diabetes .</brief_summary>
	<brief_title>Basal Bolus Insulin Aspart Including Insulin NPH Biphasic Insulin Aspart Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes Currently treat human insulin insulin analogue least 3 month , without combination OADs HbA1c 8.010.5 % Body mass index ( BMI ) 35.0 kg/m2 Able willing perform selfmonitoring blood glucose Total daily insulin dose 1.80 IU/kg Known suspect allergy trial product relate product Pregnancy , breastfeeding , intention become pregnant judge use adequate contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>